Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.

[1]  G. Gross.  Evidence for Pleiotropic Effects of Phosphodiesterase-5 (PDE5) Inhibitors: Emerging Concepts in Cancer and Cardiovascular Medicine , 2011 .

[2]  Munir Pirmohamed,et al.  Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[3]  S. Zimeras,et al.  Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐up , 2010, American journal of hematology.

[4]  P. Dent,et al.  Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction , 2010, Proceedings of the National Academy of Sciences.

[5]  J. Zweier,et al.  Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice. , 2010, American journal of physiology. Heart and circulatory physiology.

[6]  Takeshi Kimura,et al.  Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway , 2010, Cardiovascular research.

[7]  V. Diehl,et al.  Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Lopaschuk,et al.  Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. , 2010, Toxicology.

[9]  U. Schlattner,et al.  Early effects of doxorubicin in perfused heart: transcriptional profiling reveals inhibition of cellular stress response genes. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[10]  K. Mackie,et al.  CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. , 2010, Cardiovascular research.

[11]  C. Gennings,et al.  Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells , 2010, Breast Cancer Research and Treatment.

[12]  K. Pillai,et al.  Diclofenac Sodium, a Nonselective Nonsteroidal Anti-Inflammatory Drug Aggravates Doxorubicin-Induced Cardiomyopathy in Rats , 2010, Journal of cardiovascular pharmacology.

[13]  Se-Chan Kim,et al.  Extracellular Heat Shock Protein 60, Cardiac Myocytes, and Apoptosis , 2009, Circulation research.

[14]  D. Kass,et al.  Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. , 2009, Journal of molecular and cellular cardiology.

[15]  W. Gomaa,et al.  Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. , 2009, Pharmacological research.

[16]  S. Lancel,et al.  NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. , 2009, Biochemical and biophysical research communications.

[17]  R. Autschbach,et al.  Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  C. Maggi,et al.  ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat. , 2009, Vascular pharmacology.

[19]  D. Hydock,et al.  Anandamide Preserves Cardiac Function and Geometry in an Acute Doxorubicin Cardiotoxicity Rat Model , 2009, Journal of cardiovascular pharmacology and therapeutics.

[20]  B. Yeğen,et al.  Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage , 2009, Free radical research.

[21]  M. Štěrba,et al.  Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron , 2009, Pharmacological reports : PR.

[22]  M. Carraway,et al.  Heme Oxygenase-1 Regulates Cardiac Mitochondrial Biogenesis via Nrf2-Mediated Transcriptional Control of Nuclear Respiratory Factor-1 , 2008, Circulation research.

[23]  Xiaohong Wang,et al.  Heat Shock Protein 20 Interacting With Phosphorylated Akt Reduces Doxorubicin-Triggered Oxidative Stress and Cardiotoxicity , 2008, Circulation research.

[24]  K. Rayner,et al.  Extracellular Release of the Atheroprotective Heat Shock Protein 27 Is Mediated by Estrogen and Competitively Inhibits acLDL Binding to Scavenger Receptor-A , 2008, Circulation research.

[25]  W. Tsai,et al.  Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Relling,et al.  Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline‐related congestive heart failure after childhood cancer , 2008, Cancer.

[27]  Jagmeet P. Singh,et al.  Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy. , 2008, The American journal of cardiology.

[28]  B. Tsui,et al.  Detection of Dose Response in Chronic Doxorubicin-Mediated Cell Death with Cardiac Technetium 99m Annexin V Single-Photon Emission Computed Tomography , 2008, Molecular imaging.

[29]  S. Felix,et al.  Toll‐like receptor‐4 deficiency attenuates doxorubicin‐induced cardiomyopathy in mice , 2008, European journal of heart failure.

[30]  D. Neuberg,et al.  Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Aggarwal,et al.  Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. , 2008, Ultrasound in medicine & biology.

[32]  B. Ghaleh,et al.  The volume‐sensitive chloride channel inhibitors prevent both contractile dysfunction and apoptosis induced by doxorubicin through PI3kinase, Akt and Erk 1/2 , 2008, European journal of heart failure.

[33]  M. Joyeux-faure,et al.  Erythropoietin Pretreatment Protects Against Acute Chemotherapy Toxicity in Isolated Rat Hearts , 2008, Experimental biology and medicine.

[34]  M. Carraway,et al.  The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. , 2007, The Journal of clinical investigation.

[35]  U. Völker,et al.  The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. , 2007, Cancer research.

[36]  C. Szabó,et al.  Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. , 2007, American journal of physiology. Heart and circulatory physiology.

[37]  J. Berkhof,et al.  The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study , 2007, British Journal of Cancer.

[38]  Francis G Spinale,et al.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.

[39]  J. Bergh,et al.  Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  L. Liaudet,et al.  Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. , 2007, Journal of the American College of Cardiology.

[41]  G. Gao,et al.  [Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line]. , 2007, Zhongguo shi yan xue ye xue za zhi.

[42]  M. Picard,et al.  Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury, Dysfunction, and Mortality Induced by Doxorubicin , 2007, Circulation.

[43]  A. Geist,et al.  Dexrazoxane prevents doxorubicin‐induced long‐term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats , 2007, British journal of pharmacology.

[44]  N. Narula,et al.  Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model. , 2007, Journal of the American College of Cardiology.

[45]  G. Takemura,et al.  Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. , 2007, Progress in cardiovascular diseases.

[46]  C. Chen,et al.  [Effects of oxymatrine on expression of nuclear factor kappa B in kidneys of rats with adriamycin-induced chronic renal fibrosis]. , 2007, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[47]  L. Gama,et al.  Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. , 2007, Cancer research.

[48]  A. Daiber,et al.  Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. , 2007, Free radical biology & medicine.

[49]  L. Constine,et al.  Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Bast,et al.  Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells , 2007, British Journal of Cancer.

[51]  Hongli Li,et al.  Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats. , 2006, Journal of biochemistry and molecular biology.

[52]  A. Dogan,et al.  Protective effects of carvedilol against anthracycline-induced cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[53]  Yusu Gu,et al.  erbB2 is required for G protein-coupled receptor signaling in the heart , 2006, Proceedings of the National Academy of Sciences.

[54]  Hyung-Ryong Kim,et al.  Protective effect of calceolarioside on adriamycin-induced cardiomyocyte toxicity. , 2006, European journal of pharmacology.

[55]  Ye Xiong,et al.  Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. , 2006, Free radical biology & medicine.

[56]  G. Panjrath,et al.  Monitoring chemotherapy-induced cardiotoxicity: Role of cardiac nuclear imaging , 2006, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[57]  A. Ballestrero,et al.  Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. , 2006, Cardiovascular research.

[58]  P. Russell,et al.  Subacute anthracycline cardiotoxicity. , 2006, Heart, lung & circulation.

[59]  M. Pfreundschuh,et al.  NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.

[60]  S. Radulović,et al.  Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice. , 2005, Basic & clinical pharmacology & toxicology.

[61]  P. Schroeder,et al.  METABOLISM OF THE ONE-RING OPEN METABOLITES OF THE CARDIOPROTECTIVE DRUG DEXRAZOXANE TO ITS ACTIVE METAL-CHELATING FORM IN THE RAT , 2005, Drug Metabolism and Disposition.

[62]  D. Richardson,et al.  Molecular Pharmacology of the Interaction of Anthracyclines with Iron , 2005, Molecular Pharmacology.

[63]  J. Joseph,et al.  Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. , 2005, The Biochemical journal.

[64]  T. Wallimann,et al.  Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. , 2005, American journal of physiology. Heart and circulatory physiology.

[65]  P. Fisher,et al.  Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity , 2005, Circulation.

[66]  Xinxin Guo,et al.  Heat Shock Protein 90 Stabilization of ErbB2 Expression Is Disrupted by ATP Depletion in Myocytes* , 2005, Journal of Biological Chemistry.

[67]  Jeong-Hwa Lee,et al.  Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment , 2005, Molecular and Cellular Biochemistry.

[68]  C. Leeuwenburgh,et al.  Doxorubicin treatment in vivo activates caspase‐12 mediated cardiac apoptosis in both male and female rats , 2004, FEBS letters.

[69]  I. Kubota,et al.  Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout Mice , 2004, Circulation.

[70]  C. Hudis,et al.  Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. , 2004, Clinical breast cancer.

[71]  B. Ghaleh,et al.  Volume‐sensitive chloride channels (ICl,vol) mediate doxorubicin‐induced apoptosis through apoptotic volume decrease in cardiomyocytes , 2004, Fundamental & clinical pharmacology.

[72]  C. Canter,et al.  Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[73]  T. Iyanagi,et al.  Human neuronal nitric oxide synthase can catalyze one-electron reduction of adriamycin: role of flavin domain. , 2004, Archives of biochemistry and biophysics.

[74]  S. Lipsitz,et al.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. , 2004, The New England journal of medicine.

[75]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[76]  P. Merlet,et al.  Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy , 2004, British Journal of Cancer.

[77]  Xinxin Guo,et al.  Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes* , 2004, Journal of Biological Chemistry.

[78]  A. Garnier,et al.  Energy metabolism in heart failure , 2004, The Journal of physiology.

[79]  D. Stewart,et al.  Conditional Cardiac Overexpression of Endothelin-1 Induces Inflammation and Dilated Cardiomyopathy in Mice , 2004, Circulation.

[80]  R. Benza,et al.  Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[81]  Manuela M. Santos,et al.  Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. , 2003, Blood.

[82]  Ping H Wang,et al.  Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. , 2003, Journal of molecular and cellular cardiology.

[83]  R. Brook,et al.  Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase , 2003, Vascular medicine.

[84]  Suwei Wang,et al.  Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. , 2002, The Biochemical journal.

[85]  M. Shigekawa,et al.  Doxorubicin directly binds to the cardiac-type ryanodine receptor. , 2002, Life sciences.

[86]  D. Sawyer,et al.  Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1&bgr; and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity , 2002, Circulation.

[87]  P. Voûte,et al.  Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  J. Bauer,et al.  Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase , 2002, British journal of pharmacology.

[89]  J. Joseph,et al.  Doxorubicin-induced Apoptosis Is Associated with Increased Transcription of Endothelial Nitric-oxide Synthase , 2001, The Journal of Biological Chemistry.

[90]  M. Gad,et al.  Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. , 2001, Pharmacology & toxicology.

[91]  D. Fitzgerald,et al.  Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. , 2001, The Journal of clinical investigation.

[92]  A. Bast,et al.  New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity. , 2001, Free radical biology & medicine.

[93]  H. Hayakawa,et al.  Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. , 2001, Medical and pediatric oncology.

[94]  T. Miyauchi,et al.  A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[95]  C. Maggi,et al.  Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. , 2001, European journal of pharmacology.

[96]  Z. Qian,et al.  Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. , 2001, Life sciences.

[97]  T. Lüscher,et al.  Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs , 2000, Circulation.

[98]  R. V. Vander Heide,et al.  Molecular basis of anthracycline-induced cardiotoxicity and its prevention. , 2000, Molecular genetics and metabolism.

[99]  T. Galeotti,et al.  Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. , 2000, Cancer research.

[100]  C. Klersy,et al.  Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. , 2000, American heart journal.

[101]  M. Runge,et al.  Doxorubicin-Induced Cardiomyopathy , 2000 .

[102]  N. Dhalla,et al.  Role of oxidative stress in cardiovascular diseases , 2000, Journal of hypertension.

[103]  M. L. Greenberg,et al.  The biosynthesis and functional role of cardiolipin. , 2000, Progress in lipid research.

[104]  L. Bertoli,et al.  Transfusion iron overload in adults with acute leukemia: manifestations and therapy. , 2000, The American journal of the medical sciences.

[105]  D. Jain,et al.  Cardiotoxicity of doxorubicin and other anthracycline derivatives , 2000, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[106]  Junying Yuan,et al.  Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β , 2000, Nature.

[107]  T. Yokoyama,et al.  Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. , 1999, Circulation research.

[108]  J. Jaffrezou,et al.  L‐carnitine prevents doxorubicin‐induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  A. Bordoni,et al.  The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes. , 1999, Biochimica et biophysica acta.

[110]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[111]  G. Hasenfuss,et al.  Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. , 1999, Circulation.

[112]  H. Crijns,et al.  Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables , 1999, Heart.

[113]  L. Papadopoulou,et al.  Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression. , 1999, Biochemical pharmacology.

[114]  R. Nagai,et al.  Elevated B-type natriuretic peptide levels after anthracycline administration. , 1998, American heart journal.

[115]  H. El-kashef,et al.  Captopril ameliorates myocardial and hematological toxicities induced by adriamycin , 1998, Biochemistry and molecular biology international.

[116]  C. Mancuso,et al.  The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein‐1 in cytosolic fractions from human myocardium , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[117]  A. Bast,et al.  Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[118]  K. Pritchard,et al.  Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. , 1997, Biochemistry.

[119]  A. Matsuzaki,et al.  Anthracycline‐induced cardiotoxicity in children with malignancies , 1997, Acta paediatrica Japonica : Overseas edition.

[120]  K. Wallace,et al.  Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. , 1996, Journal of molecular and cellular cardiology.

[121]  B. Jensen,et al.  Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy , 1996, The Lancet.

[122]  A. C. Zable,et al.  Hydrogen Peroxide Stimulates the Ca2+ Release Channel from Skeletal Muscle Sarcoplasmic Reticulum (*) , 1995, The Journal of Biological Chemistry.

[123]  A. Bast,et al.  Monohydroxyethylrutoside as protector against chronic doxorubicin‐induced cardiotoxicity , 1995, British journal of pharmacology.

[124]  G. Levitt,et al.  Cardiac function in Wilms' tumor survivors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  E J Orav,et al.  Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. , 1995, The New England journal of medicine.

[126]  F. Bu'Lock,et al.  Increased risk of cardiac dysfunction after anthracyclines in girls. , 1995, Medical and pediatric oncology.

[127]  A. Bast,et al.  Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice. , 1993, Cancer research.

[128]  J. Burnett,et al.  Endothelin-mediated cardiorenal hemodynamic and neuroendocrine effects are attenuated by nitroglycerin in vivo. , 1993, American Journal of Hypertension.

[129]  A. Allen,et al.  The cardiotoxicity of chemotherapeutic drugs. , 1992, Seminars in oncology.

[130]  J. Kupersmith,et al.  Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. , 1992, Journal of the American College of Cardiology.

[131]  R. Ulrich,et al.  A digitized-fluorescence-imaging study of mitochondrial Ca2+ increase by doxorubicin in cardiac myocytes. , 1992, The Biochemical journal.

[132]  R. Berg,et al.  Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. , 1992, Journal of the American College of Cardiology.

[133]  L. Toll,et al.  L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations. , 1991, The Journal of clinical investigation.

[134]  K. Kashfi,et al.  Inhibition of mitochondrial carnitine palmitoyltransferases by adriamycin and adriamycin analogues. , 1990, Biochemical pharmacology.

[135]  J. Glickson,et al.  The relationship between cardiac function and metabolism in acute adriamycin-treated perfused rat hearts studied by 31P and 13C NMR spectroscopy. , 1990, Journal of molecular and cellular cardiology.

[136]  A. Williams,et al.  Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum. , 1990, Circulation research.

[137]  B. Hasinoff.  The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[138]  H. Pouleur,et al.  Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. , 1989, American heart journal.

[139]  T. Ruigrok,et al.  Effects of the anti-cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 31P-NMR and implications for adriamycin-induced cardiotoxicity. , 1987, Biochimica et biophysica acta.

[140]  M. Rich,et al.  Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. , 1987, Annals of internal medicine.

[141]  R. Peshock,et al.  Nuclear magnetic resonance study of high‐energy phosphate stores in models of adriamycin cardiotoxicity , 1986, Magnetic resonance in medicine.

[142]  J. Hannigan,et al.  Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. , 1986, Cancer research.

[143]  M. Goris,et al.  Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. , 1983, American heart journal.

[144]  W. Mcguire,et al.  Doxorubicin (adriamycin) cardiomyopathy. , 1983, The Western journal of medicine.

[145]  M. Bristow.  Toxic cardiomyopathy due to doxorubicin. , 1982, Hospital practice.

[146]  M. Cohen,et al.  Reversible doxorubicin-induced congestive heart failure. , 1982, Archives of internal medicine.

[147]  P. Caroni,et al.  The cardiotoxic antibiotic doxorubicin inhibits the Na+/Ca2+ exchange of dog heart sarcolemmal vesicles , 1981, FEBS letters.

[148]  E. Goormaghtigh,et al.  Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity. , 1980, Biochemical pharmacology.

[149]  D. Williams,et al.  Solution chemistry studies of adriamycin--iron complexes present in vivo. , 1980, European journal of cancer.

[150]  M. Shah,et al.  An effective low‐dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients , 1980, Cancer.

[151]  S. Kaplan,et al.  Doxorubicin cardiotoxicity in children. , 1980, The Journal of pediatrics.

[152]  J. J. Buckley,et al.  Report of Three Cases , 1962 .

[153]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[154]  W. Gradishar,et al.  American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  D. S. St. Clair,et al.  The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. , 2006, Cardiovascular research.

[156]  Y. Kakinuma,et al.  Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. , 2006, Journal of pharmacological sciences.

[157]  M. Isobe,et al.  Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. , 2005, Journal of molecular and cellular cardiology.

[158]  R. Erttmann,et al.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence , 2004, Journal of Cancer Research and Clinical Oncology.

[159]  J. Michálek,et al.  The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography. , 2003, Neoplasma (Bratislava).

[160]  I. Kubota,et al.  Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. , 2003, Cardiovascular research.

[161]  J. Rouleau,et al.  Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure. , 1998, Journal of cardiovascular pharmacology.

[162]  A. Carr,et al.  Free radical inactivation of rabbit muscle creatinine kinase: catalysis by physiological and hydrolyzed ICRF-187 (ICRF-198) iron chelates. , 1994, Free radical research.

[163]  M. Scheulen,et al.  In vivo studies on adriamycin-induced lipid peroxidation and effects of ferrous ions. , 1980, Developments in toxicology and environmental science.

[164]  J. Doroshow,et al.  Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. , 1980, The Journal of clinical investigation.